Long Term Safety Following GM T Cell Therapy

0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
Non-interventionalN/A1 trial
Active Trials
NCT06798298Recruiting50Est. Jun 2040

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
2031
RegeneronNon-interventional

Clinical Trials (1)

Total enrollment: 50 patients across 1 trials

NCT06798298RegeneronNon-interventional

A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

Start: Nov 2025Est. completion: Jun 204050 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 50 patients
1 companies competing in this space